An Efficient Tool for Surveying CRF01_AE HIV Type 1 Resistance in Thailand to Combined Stavudine–Lamivudine–Nevirapine Treatment Mutagenically Separated PCR Targeting M184IV.

Under programs organized by the government of Thailand, HIV-1-infected patients have been treated since 2002 with several regimens, including a tablet known as GPOvir, which contains lamivudine, stavudine, and nevirapine. The aim of this study was to establish an effective assay, based on mutagenically separated PCR (MS-PCR), with the goal of surveying GPOvir-resistant HIV-1 cases. To determine the target mutation point for the assay, we analyzed the patterns of acquired drug resistance in plasma samples from GPOvir-failed cases. Of 428 HIV-1-infected individuals treated with GPOvir at Lampang Hospital in northern Thailand from 2002 to 2004, 66 had detectable viral loads after 3 months of treatment. The HIV-1 sequences of these 66 GPOvir-failed cases and 55 pre-GPOvir baseline samples were analyzed. The most prevalent drug resistance mutation among the samples was the lamivudine resistance M184IV mutation. Based on this finding, we developed a new MS-PCR assay to detect the M184IV mutation, and evaluated the assay performance for detecting GPOvir-resistant CRF01_AE cases. Comparing the results of M184IV MS-PCR and sequence analyses, we found a concordance rate of 95 and an overall sensitivity of the M184IV MS-PCR for detecting GPOvir-resistant cases of 79. Considering the relatively low price of the assay, approximately 12.50 per sample, M184IV MS-PCR may be a candidate for monitoring a large number of GPOvir-treated patients, particularly in developing nations. [ABSTRACT FROM AUTHOR]